3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Nivolumab
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cisplatin
4
pembrolizumab
3
cabozantinib
3
avelumab
3
Ipilimumab
3
Carboplatin
3
CTLA-4 Antigen
3
enfortumab vedotin
2
Immunoglobulin G
2
Disulfides
2
Biopsy
2
tremelimumab
1
trastuzumab deruxtecan
1
tocilizumab
1
tamibarotene
1
relatlimab
1
eribulin
1
erdafitinib
1
durvalumab
1
atezolizumab
1
Propranolol
1
Platinum
1
Leucovorin
1
Lenalidomide
1
Fluorouracil
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urethral Neoplasms
×
tamibarotene
×
1 year
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled